{
  "ticker": "DVA",
  "cik": "0000927066",
  "company_name": "DaVita",
  "corrected_name": "DaVita",
  "wiki_title_used": "DaVita",
  "exists": true,
  "raw_text": "DaVita Inc. provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation. The company has a 37% market share in the U.S. dialysis market. It is incorporated in Delaware and headquartered in Denver.\nIn 2023, 67% of the company's revenues came from Medicare and other government-based health insurance programs. In 2023, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 33% of revenues in 2023, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.\nThe company is ranked 341st on the Fortune 500.\n\nHistory\nThe company was founded in 1979 as Medical Ambulatory Care, Inc., a subsidiary of National Medical Enterprises, Inc. (now Tenet Healthcare). \nIn August 1994, 70% of the company was acquired by DLJ Merchant Banking Partners in a leveraged buyout for $75.5 million,  including a $10.5 million investment by DLJ. The company then changed its name to Total Renal Care Holdings, Inc.\nIn October 1995, the company became a public company via an initial public offering, raising $107 million. By December 1996, DLJ had made a 386% return on its $10.5 million investment.\n\nAcquisitions and divestments\nOn February 27, 1998, the company acquired Renal Treatment Centers for $1.3 billion in stock. The integration went poorly and in July 1999, the CEO and CFO resigned. After tripling in value between 1995 and 1998, by July 1999, the stock price was down 71% year-to-date. In October 1999, Kent J. Thiry, then 43 years old, was named CEO.\nIn 2000, the company sold its non-U.S. operations. In October 2000, the company was renamed DaVita Inc. The name \"DaVita\" was derived from the Italian language phrase \"Dare Vita\", which means \"to give life\".\nIn October 2005, the company acquired Gambro Healthcare. \nIn 2012, DaVita acquired Healthcare Partners for $4.42 billion. In September 2016, Healthcare Partners was renamed DaVita Medical Group. In June 2019, the division was sold to UnitedHealth Group's Optum division for $4.3 billion.\nIn 2014, DaVita acquired Colorado Springs Health Partners, with 600 employees and 110,000 patients. \nIn March 2016, it acquired the Everett Clinic Medical Group, a 20-site physicians practice with 315,000 patients in the Seattle area, for $385 million.  \nIn May 2017, it acquired WellHealth Quality Care.\n\nLegal issues\nIn October 2014, the company agreed to pay $350 million to settle claims that it provided illegal kickbacks to doctors.\nIn June 2015, the company agreed to pay $450 million to settle allegations that it unnecessarily disposed of drugs and then billed the U.S. federal government for this waste.\nIn June 2018, a jury awarded the families of 3 of the company's patients $383 million in wrongful death claims after the patients died from cardiac arrest after undergoing treatment at DaVita centers.\nIn October 2018, it agreed to pay $270 million to settle allegations that it violated the False Claims Act by providing inaccurate information that caused Medicare Advantage Plans to receive inflated payments. James Swoben, a whistleblower, received $10 million. \nIn July 2021, a federal grand jury indicted DaVita and former CEO Kent Thiry on charges of labor market collusion alleging participation in conspiracies with Surgical Care Affiliates to suppress competition for the services of certain senior-level employees. The company and Thiry were acquitted by a jury in April 2022. In October 2021, the Federal Trade Commission imposed limits on the company engaging in more mergers in Utah because of its history of buying up competitors.\nIn 2024, the Federal Trade Commission began investigating Davita along with Fresenius Medical Care under allegations they use illegal tactics to push smaller companies out of the market.\nIn May 2025, the benefits fund of the United Food and Commercial Workers Local 1776 filed a proposed class-action lawsuit against DaVita and Fresenius Medical Care, a rival dialysis provider, alleging that the two companies illegally conspired to inflate treatment costs for dialysis patients by billions of dollars.\n\nReferences\nExternal links\n\nOfficial website\nBusiness data for DaVita Inc.:",
  "clean_text": "DaVita Inc. provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation. The company has a 37% market share in the U.S. dialysis market. It is incorporated in Delaware and headquartered in Denver. In 2023, 67% of the company's revenues came from Medicare and other government-based health insurance programs. In 2023, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 33% of revenues in 2023, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs. The company is ranked 341st on the Fortune 500. History The company was founded in 1979 as Medical Ambulatory Care, Inc., a subsidiary of National Medical Enterprises, Inc. (now Tenet Healthcare). In August 1994, 70% of the company was acquired by DLJ Merchant Banking Partners in a leveraged buyout for $75.5 million, including a $10.5 million investment by DLJ. The company then changed its name to Total Renal Care Holdings, Inc. In October 1995, the company became a public company via an initial public offering, raising $107 million. By December 1996, DLJ had made a 386% return on its $10.5 million investment. Acquisitions and divestments On February 27, 1998, the company acquired Renal Treatment Centers for $1.3 billion in stock. The integration went poorly and in July 1999, the CEO and CFO resigned. After tripling in value between 1995 and 1998, by July 1999, the stock price was down 71% year-to-date. In October 1999, Kent J. Thiry, then 43 years old, was named CEO. In 2000, the company sold its non-U.S. operations. In October 2000, the company was renamed DaVita Inc. The name \"DaVita\" was derived from the Italian language phrase \"Dare Vita\", which means \"to give life\". In October 2005, the company acquired Gambro Healthcare. In 2012, DaVita acquired Healthcare Partners for $4.42 billion. In September 2016, Healthcare Partners was renamed DaVita Medical Group. In June 2019, the division was sold to UnitedHealth Group's Optum division for $4.3 billion. In 2014, DaVita acquired Colorado Springs Health Partners, with 600 employees and 110,000 patients. In March 2016, it acquired the Everett Clinic Medical Group, a 20-site physicians practice with 315,000 patients in the Seattle area, for $385 million. In May 2017, it acquired WellHealth Quality Care. Legal issues In October 2014, the company agreed to pay $350 million to settle claims that it provided illegal kickbacks to doctors. In June 2015, the company agreed to pay $450 million to settle allegations that it unnecessarily disposed of drugs and then billed the U.S. federal government for this waste. In June 2018, a jury awarded the families of 3 of the company's patients $383 million in wrongful death claims after the patients died from cardiac arrest after undergoing treatment at DaVita centers. In October 2018, it agreed to pay $270 million to settle allegations that it violated the False Claims Act by providing inaccurate information that caused Medicare Advantage Plans to receive inflated payments. James Swoben, a whistleblower, received $10 million. In July 2021, a federal grand jury indicted DaVita and former CEO Kent Thiry on charges of labor market collusion alleging participation in conspiracies with Surgical Care Affiliates to suppress competition for the services of certain senior-level employees. The company and Thiry were acquitted by a jury in April 2022. In October 2021, the Federal Trade Commission imposed limits on the company engaging in more mergers in Utah because of its history of buying up competitors. In 2024, the Federal Trade Commission began investigating Davita along with Fresenius Medical Care under allegations they use illegal tactics to push smaller companies out of the market. In May 2025, the benefits fund of the United Food and Commercial Workers Local 1776 filed a proposed class-action lawsuit against DaVita and Fresenius Medical Care, a rival dialysis provider, alleging that the two companies illegally conspired to inflate treatment costs for dialysis patients by billions of dollars."
}